Author | Yang-Min Ning, MD, PhD

Articles

Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma

November 01, 2007

Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.